Breaking News
Sort by:
Top Post
NHS Slashes Longest Elective and Cancer Patient Waiting Lists
The number of people waiting over 18 months for NHS care has fallen again despite […]
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
Incyte today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved […]
Novartis Trial Shows Benefit in Patients with Breast Cancer
Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III […]
EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis
EVERSANA, a leading provider of commercialization services to the life science industry, today announced a […]
Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer
Bayer further expands the global clinical development program for NUBEQA (darolutamide) in prostate cancer. The […]
Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care
Massive Bio, a private AI-enabled oncology startup that provides virtual and in-person concierge services for […]
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, has […]
Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution
Lunit, a leading global provider of AI-powered cancer solutions, today announced that its AI solution […]
China's First Personalized Neoantigen-Targeted Cancer Vaccine Receives NMPA's Clinical Trial Approval
According to the latest data released in the Clinical Trials Implied Approval section on the […]
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
Pfizer and Astellas Pharma have announced positive topline results from the Phase 3 EMBARK trial […]
- Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Read more
- Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Read more
- Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Read more
- Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Read more
- Implantica Launches RefluxStop™ in Italy Read more